MOTIV BTK Randomized Controlled Trial
Part of paid clinical trials in St. Helena, California.
- Sponsor
- REVA Medical, Inc.
- Study ID
- NCT05406622
- Status
- Recruiting
Conditions
- Critical Limb Ischemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MOTIV Sirolimus-Eluting Bioresorbable Scaffold — DEVICEParticipants will receive the MOTIV device
- Percutaneous Transluminal Angioplasty (PTA) Device — DEVICEParticipants will receive PTA treatment
Study Details
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
Key Dates
- Start date
- Jun 10, 2022
- Status verified
- Apr 2025
- Primary completion
- Sep 30, 2025
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 292 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MOTIV Sirolimus-Eluting Bioresorbable ScaffoldParticipants who receive the MOTIV device will be included in this arm
- Active Comparator: Percutaneous Transluminal Angioplasty (PTA)Participants who receive PTA treatment will be included in this arm
Primary Outcome Measure
Primary Efficacy Endpoint: Composite of Limb Salvage and Primary Patency [ Time Frame: 6 Months ]
Central Contacts
- Danielle Gram+1 (858) 966-3021
- Jeff Anderson+1 (858) 966-3038
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Adventist Health | St. Helena | California | 94574 | Ehrin Armstrong Ehrin Armstrong, MD (PRINCIPAL_INVESTIGATOR) |
| UnityPoint Health Trinity Bettendorf Hospital | Bettendorf | Iowa | 52722 | Gail Shammas Nicolas Shammas, MD (PRINCIPAL_INVESTIGATOR) Amit Bahia, MD (SUB_INVESTIGATOR) |
| Cardiovascular Medicine PC | Davenport | Iowa | 52803 | Gail Shammas Nicolas Shammas, MD (PRINCIPAL_INVESTIGATOR) Amit Bahia, MD (SUB_INVESTIGATOR) |
Find similar trials in St. Helena, CA
Related Studies
- PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening IschemiaRecruiting · LimFlow, Inc. · La Jolla, California
- Nutrition in Patient With Critical Limb IschemiaEARLY_PHASE1 · Recruiting · Boston Medical Center · Boston, Massachusetts
- Trial to Assess Chelation Therapy in Critical Limb IschemiaPHASE3 · Recruiting · Mt. Sinai Medical Center, Miami · Miami Beach, Florida
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the KneePHASE3 · Recruiting · Mercator MedSystems, Inc. · Houma, Louisiana